Kuchyne na miru

Pharmaceutical Executive March 2019

March 2019 | Volume 39, Issue 3
Pharmaceutical Executive March 2019
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.
In the News
By Pharmaceutical Executive Editors
Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.
From the Editor
That often muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.
Perspectives from big pharma and the rare disease space on how patient advocacy is evolving as a corporate function.
Working group explores the challenges of patient support programs and market research programs for pharmacovigilance professionals—and solutions currently being put into practice.
Amicus Therapeutics CEO John Crowley discusses the growing role of the patient-centered view in company culture—not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.
Efforts to collaborate around patient engagement in every phase of product development are illustrating the growing relationship between disease advocacy groups and industry.
Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer" connection and the shifts taking place in making patient-centric programs and tools more alive for patients.
An industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).
Benchmark survey assesses the industry’s progress so far in moving from words to action in its approach to patient centricity.
Wide-ranging probes to target marketing, pricing, and access. Jill Wechsler reports.
Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.
Eloxx Pharmaceuticals CEO Bob Ward on addressing this underserved patient segment.
Special Sponsored Section
After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo—thrusting the pharma and medtech sectors into the spotlight.

lorem ipsum